Biosensia
Point-of-Care in-vitro diagnostics company that has a novel point-of-care platform, RapiPlex.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2016 | 2017 | 2019 | 2020 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 60 % | - | (61 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (124 %) | (27 %) | (1069 %) | (3074 %) |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (84 %) | (2 %) | (995 %) | (2833 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Biosensia is an innovative biotech startup based in Ireland, specializing in in vitro diagnostics, which means they develop tests that can be performed on samples like blood or tissue to diagnose diseases. Their flagship product, RapiPlex, is a point-of-care diagnostic system. This system uses proprietary technologies to deliver both quantitative (numerical) and qualitative (descriptive) laboratory-quality test results quickly and efficiently. However, it's important to note that RapiPlex is currently approved for research purposes only and not for clinical use.
The company primarily serves research institutions, universities, and biotech firms that require advanced diagnostic tools for their studies. By focusing on the research market, Biosensia operates in the broader healthcare and biotechnology sectors, which are rapidly growing due to increasing demand for advanced diagnostic solutions.
Biosensia's business model revolves around the development and licensing of their proprietary diagnostic platform, RapiPlex. They generate revenue by licensing their technology to other companies and research institutions. This model allows them to focus on innovation and development while leveraging the distribution and commercialization capabilities of their partners.
In summary, Biosensia is a pioneering biotech company that offers advanced diagnostic solutions for the research market. Their innovative RapiPlex system provides high-quality test results and is available for licensing, enabling them to generate revenue through partnerships.
Keywords: Biotech, Diagnostics, Research, Point-of-Care, RapiPlex, Licensing, Healthcare, Innovation, Technology, Ireland.